| Autor: |
Gerhards, Ramona, Pfeffer, Lena Kristina, Lorenz, Jessica, Starost, Laura, Nowack, Luise, Thaler, Franziska S., Schlüter, Miriam, Rübsamen, Heike, Macrini, Caterina, Winklmeier, Stephan, Mader, Simone, Bronge, Mattias, Grönlund, Hans, Feederle, Regina, Hung-En Hsia, Lichtenthaler, Stefan F., Merl-Pham, Juliane, Hauck, Stefanie M., Kuhlmann, Tanja, Bauer, Isabel J., Beltran, Eduardo, Gerdes, Lisa Ann, Mezydlo, Aleksandra, Bar-Or, Amit, Banwell, Brenda, Khademi, Mohsen, Olsson, Tomas, Hohlfeld, Reinhard, Lassmann, Hans, Kümpfel, Tania, Kawakami, Naoto, Meinl, Edgar |
| Rok vydání: |
2020 |
| DOI: |
10.6084/m9.figshare.13311369 |
| Popis: |
Additional file 1. Supplementary Methods. Fig. S1. Cell-based assays to detect antibodies to OMGP. Fig. S2. Reactivity to OMGP in both CBAs and isotypes of OMGP-specific Abs of patients scored positive. Fig. S3. Affinity-purification of OMGP-specific Abs from MS patient 2492. Fig. S4. Fluorospot assay identifies MS patients with OMGPspecific T cells. Fig. S5. Characterization of new mAbs to OMGP. Fig. S6. ELISA to detect sOMGP. Fig. S7. Characterization of OMGP-specific T cells. Fig. S8. OMGP-specific T cells pave the way for focal demyelination in the cortex. Fig. S9. Immune complexes of OMGP and anti-OMGP activate phagocytes. Table S1. Subjects used for screening of anti-OMGP Abs. Table S2. Clinical characteristics of patients with Abs to OMGP. Table S3. Subjects used for analysis of OMGP-specific T cells. Table S4. Patients used for quantification of sOMGP in the CSF. References [2, 9, 18, 27, 45, 49, 55–57, 77–80] are cited in additional file 1. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
